Selpercatinib for RET-altered cancers
Treatments studied
Part of Cancer, Hormones & metabolism, Lungs & breathing clinical trials.
This trial tests an oral drug called selpercatinib for people with certain cancers that have changes in the RET gene. It is for patients in India with advanced non-small cell lung cancer, medullary thyroid cancer, or other solid tumors that have not responded well to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these cancers: advanced non-small cell lung cancer with a RET fusion, advanced medullary thyroid cancer, advanced thyroid cancer with a RET fusion, or another advanced solid tumor with a RET fusion.
- Your tumor must have a RET gene change (fusion or mutation), confirmed by a lab test like PCR or NGS.
- You must have had the cancer progress on or after prior treatment, unless you have no other good options.
- You must be 12 years or older for thyroid or medullary thyroid cancer; adults can also join for lung cancer.
- You must be in general good health, able to do daily activities (ECOG 0-2).
- If you are able to have children, you must agree to use effective birth control during treatment and for 2 weeks after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving targeted drugs before surgery can help shrink advanced thyroid cancers, making them easier to remove. It uses your tumor's genetic profile to choose the best treatment for you.
This study tests whether a targeted drug called selpercatinib, taken before radioactive iodine therapy, can help treat thyroid cancer in children and young adults who have a specific genetic change (RET fusion or mutation). The drug may make the cancer more sensitive to the radioactive iodine treatment that follows.
This trial tests whether combining a targeted pill (selpercatinib) with a radioactive iodine dose (I-131) can shrink thyroid cancer that has spread and no longer responds to radioactive iodine. It is for RET fusion–positive (genetically driven) thyroid cancers where the cancer cannot reliably absorb iodine anymore.
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
This trial tests an investigational drug, SNH-118110, for people with advanced solid tumors that have a specific genetic change called RET. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a combination of two medicines (pembrolizumab and lenvatinib) for people with advanced non-small cell lung cancer that has a specific RET gene change. The treatment may help slow down or shrink the cancer, and the study checks how well people tolerate it.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.